Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2267819 | 0.94 | KIF11 (0.55) | TAAR1IDO1KIF11MAOB | |
| SCHEMBL5569633 | 0.88 | MAPK14 (0.49) | TAAR1IDO1KMT2AMAOB | |
| SCHEMBL18003515 | 0.84 | MAOB (0.66) | MAOBPTPN1 | |
| SCHEMBL30753815 | 0.81 | IDO1 (0.46) | TAAR1IDO1KIF11KMT2AMAOB | |
| SCHEMBL4660565 | 0.81 | IDO1 (0.46) | TAAR1IDO1KIF11KMT2AMAOB | |
| SCHEMBL67365 | 0.80 | TAAR1 (0.55) | TAAR1IDO1KIF11KMT2AMAOB | |
| SCHEMBL11739376 | 0.80 | PTPN1 (0.42) | TAAR1IDO1KIF11KMT2ACES2 | |
| SCHEMBL3633320 | 0.79 | TAAR1 (0.48) | TAAR1IDO1KIF11KMT2AMAOB | |
| SCHEMBL8002836 | 0.79 | TAAR1 (0.48) | TAAR1IDO1KIF11KMT2AMAOB | |
| SCHEMBL3300793 | 0.79 | TAAR1 (0.48) | TAAR1IDO1KIF11KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697227-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2014-02-19 | — | — | EP | claimed |
| WO-2012142237-A1 | FUSED IMIDAZOLE DERIVATIVES USEFUL AS IDO INHIBITORS | NEWLINK GENETICKS CORPORATION (US) | 2012-10-18 | — | — | WO | claimed |
| WO-2009032840-A1 | FLUORINE- SUBSTITUTED 2 ', 6 ' -DIMETHYL-L-TYROSINE-1, 2,3, 4-TETRAHYDR0IS0QUIN0LINE-3-CARB0XYLIC ACID PEPTIDES (DMT-TIC) FOR USE AS MYU- AND DELTA-OPIOID RECEPTOR PROBES IN | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-12 | — | — | WO | claimed |
| WO-1992006998-A1 | CYCLOPEPTIDES, A METHOD OF PREPARING THEM, AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM KG (DE) | 1992-04-30 | — | — | WO | claimed |
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | LMITO THERAPEUTICS INC. (KR) | 2026-03-10 | — | — | US | disclosed |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | INST NAT SANTE RECH MED (FR) | 2025-11-20 | — | — | US | disclosed |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | PFIZER INC. (US) | 2025-03-13 | — | — | US | disclosed |
| CN-111848598-B | Heterocyclic compound, application thereof and composition containing same | 健艾仕生物医药有限公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024158698-A1 | NOVEL F-ATPASE HYDROLASE INHIBITORS | LUCY THERAPEUTICS, INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-4384519-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | Albert-Ludwigs-Universität Freiburg (DE) | 2024-06-19 | — | — | EP | disclosed |
| CN-117641958-A | Passivation material and application thereof | 隆基绿能科技股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-6194446-B1 | NON-INSULIN DEPENDENT DIABETES | ELI LILLY AND COMPANY | 2001-02-27 | — | — | US | disclosed |
| US-6121282-A | 3-(CARBOXY, AMIDO, CYANO, OR HYDROXYAMINOCARBONYL)-6 OR 7-SUBSTITUTED-1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1992006998-A1 | CYCLOPEPTIDES, A METHOD OF PREPARING THEM, AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM KG (DE) | 1992-04-30 | — | — | WO | disclosed |
| US-4267359-A | Novel carboxylic acid esters | ZOECON CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
| US-4204071-A | 4-Aryl-3-butenoic acids and lower alkyl esters | ZOECON CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
| US-4003965-A | FIRE RETARDANTS, PREEMERGENCE HERBICIDES | MONSANTO COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
| US-3984400-A | 11-Desoxy-16-aryl-ω-tetranorprostaglandins | PFIZER INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084084-A1 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | CSPP1, PRNP, RPLP2 | TAAR1 2646/4885IDO1 2521/4885KIF11 804/4885 |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | TAAR1 3002/4885IDO1 2116/4885KIF11 1100/4885 |
| US-12570613-B2 | Imidazoquinoline or benzoindazolone compound and intermediate for preparing same | NQO1, CBR1, NFE2L2 | TAAR1 2115/4885IDO1 403/4885KIF11 4420/4885 |
| US-20250353863-A1 | TRICYCLIC SPIROLACTAM COMPOUNDS WITH ANTIMYCOBACTERIAL ACTIVITY | TALDO1, TBCA, TBCD | TAAR1 1526/4885IDO1 3711/4885KIF11 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.